ARRL

Secure Site Login

News

ARRL Member Had Role in Promising RF Treatment Device for Alzheimer’s

08/06/2019

ARRL member Eric Knight, KB1EHE, played a role in the development of an RF-based Alzheimer’s disease treatment that now shows great promise. A study published today in the Journal of Alzheimer’s Disease following a months-long FDA clinical trial of the treatment protocol concluded that memory decline in most patients “appeared to have been reversed to cognitive levels equivalent to 12 months earlier” after 2 months of treatment. The clinical trial concluded last December 31 and focused on the initial efficacy of what NeuroEM Therapeutics, Inc. — the company developing the device — calls “transcranial electromagnetic treatment” (TEMT), using a noninvasive head-worn device called the MemorEMÔ.

“Results from the trial demonstrate that TEMT was safe in all eight participating patients with mild to moderate Alzheimer’s disease, and enhanced cognitive performance in seven of them, as measured by standard cognition scales,” said a news release from NeuroEM Therapeutics. Seven of the eight clinical trial patients agreed to take part in a 4-month extension study, based on the findings and the positive feedback from all participants.

“This pioneering study suggests that TEMT may be an entirely new therapeutic intervention against Alzheimer’s disease,” said NeuroEM CEO Dr. Gary Arendash. “Our bioengineering technology may be succeeding where drug therapy against this devastating disease has thus far failed. TEMT appears to be affecting the Alzheimer’s disease process through several actions directly inside neurons (brain cells), which is where we believe the disease process needs to be stopped and hopefully reversed.” Dr. Amanda Smith, Director of Clinical Research at the Byrd Alzheimer's Center and Research Institute at the University of South Florida Health — the clinical center for the study — coauthored the study.

Arendash has explained that TEMT in the 900 MHz range breaks down the small protein aggregates (amyloid oligomers) in brain cells that are thought to initiate Alzheimer’s development.

Knight, of Unionville, Connecticut, is the president of Remarkable Technolgies. He has no medical background, but several years ago, he learned of experiments that Arendash had carried out on mice specially bred to have Alzheimer’s disease, in which the mice were exposed to low levels of RF for therapeutic purposes. The effects were dramatic, sometimes even reversing the disease’s effects. Borrowing some concepts from earlier experiments with small rockets and avionics, Knight set about developing — and later patenting — a wearable device that could deliver requisite low levels of RF to a human head. NeuroEM was also developing a device, which it patented as well, and NeuroEM has filed multiple patents since then, Knight explained to ARRL. NeuroEM has an exclusive license to Knight’s patent, and his contribution is now part of the overall mix of applied technology.

As Arendash told ARRL for a March 2018 article in QST, TEMT also dramatically increases the very low energy production of Alzheimer’s-diseased brain cells by enhancing their mitochondrial function. Arendash said mitochondrial dysfunction is an early and critical event in the development of Alzheimer’s. This further leads to a general increase in brain activity. Going too high in frequency won’t penetrate the brain; go too low and the RF passes right through, Arendash said. “The combination of all three — a ‘cocktail,’ if you will — we believe stands a very good chance of working,” Arendash told ARRL.

“As an inventor and entrepreneur, all you can hope for is to have a positive impact on society, and this is about as important as it gets,” Knight told ARRL. “It’s truly the most important and proudest moment of my professional life.”



Back